Introduction {#Sec1}
============

Hypertension is a major risk factor for cardiovascular (CV) morbidity and mortality \[[@CR1]\], and antihypertensive drugs as a whole reduce that risk \[[@CR2]\]. Questions remain, however, regarding the relative benefit of specific antihypertensive drugs or classes of drugs for preventing CV-related events, including myocardial infarction, congestive heart failure, stroke, and angina pectoris.

Several meta-analyses \[[@CR3]--[@CR5]\] and large randomized trials \[[@CR6], [@CR7]\] in hypertensive patients have shown that β-blockers do not reduce CV events to the extent of other antihypertensive drug classes. Such results prompted changes to the evidence-based guidelines for the management of high blood pressure in adults, with β-blockers no longer recommended as first-line antihypertensive treatments in the US \[[@CR8]\]. Of note, the reports upon which the revised recommendations were based were non-vasodilatory β-blockers \[[@CR9]\]. Similar studies on the effect of vasodilatory β-blockers (e.g., nebivolol and carvedilol) on CV-related events are lacking in hypertensive populations. Nebivolol---a β~1~-selective adrenergic blocker with β~3~ agonistic vasodilatory properties---may confer more protection against CV events than non-vasodilatory β-blockers through its unique mechanism of action: endothelium-dependent vasodilation via nitric oxide, decreased peripheral resistance, decreased myocardial contractility, and suppression of renin activity \[[@CR10], [@CR11]\].

Unlike atenolol, nebivolol does not increase the augmentation index (a measure of central blood pressure) \[[@CR12]\], but increases cardiac stroke volume and decreases peripheral vascular resistance without reducing cardiac output \[[@CR13]\]. Furthermore, nebivolol does not decrease heart rate to the same extent as atenolol \[[@CR12], [@CR13]\]. In addition to its cardiovascular effects, nebivolol has a tolerability profile similar to placebo (2.8% AE-related discontinuations for nebivolol vs. 2.2% placebo) \[[@CR14]\] and better tolerability than several other antihypertensive drug classes, including other β-blockers \[[@CR15]\]. Yet, little is known of the comparative effectiveness of monotherapy with nebivolol and two commonly prescribed non-vasodilatory β~1~-selective blockers, atenolol and metoprolol, in reducing CV event risks. The objective of this study was to compare the real-world risk of hospitalization due to a CV event in patients with uncomplicated hypertension receiving nebivolol, atenolol, or metoprolol monotherapy.

Methods {#Sec2}
=======

All study methods are described below or in the online-only Data Supplement.

Compliance with Ethics Guidelines {#Sec3}
---------------------------------

This study is based on de-identified data collected from a health care claims database and does not contain any studies with human participants or animals performed by any of the authors, therefore informed consent was not obtained.

Study Design and Patients {#Sec4}
-------------------------

This was a retrospective claims analysis using data from IMS PharMetrics Plus™, a US national-level claims database comprising de-identified, HIPAA-compliant patient-level data. Patients with a diagnosis of hypertension (International Classification of Diseases, 9th Revision, Clinical Modification \[ICD-9-CM\] codes 401.xx-405.xx) between January 1, 2007 and June 30, 2014 were identified. The index date and index drug were defined by the first claim for a β-blocker on or after January 1, 2008 (per National Drug Codes). Inclusion criteria were assessed during the baseline period, defined as the 6-month period prior to the index date (Fig. [1](#Fig1){ref-type="fig"}). Incident users of nebivolol, atenolol, or metoprolol with continuous plan enrollment during the baseline period were included. Any non-β-blocker antihypertensives taken during the baseline period were discontinued prior to the first β-blocker monotherapy claim. Key exclusion criteria included a history of CV disorders other than hypertension (e.g., myocardial infarction \[MI\]; congestive heart failure \[CHF\]; stroke; angina pectoris; coronary artery disease \[CAD\]; coronary artery bypass graft \[CABG\]; cardiovascular disease \[CVD\]; peripheral vascular disease \[PVD\]; percutaneous coronary intervention; angioplasty; or any heart rhythm or heart rate disorders) prior to the index date or use of non-index antihypertensive drugs during the follow-up period (Fig. [1](#Fig1){ref-type="fig"}; ICD-9 codes for the exclusion criteria are available at <http://hyper.ahajournals.org>). There was no minimum follow-up period; follow-up continued until discontinuation of the index drug (≥ 90 day gap in supply), a claim for non-index β-blockers, or the end of continuous plan enrollment, whichever came first.Fig. 1Patient selection. ^a^Diagnosis of hypertension was determined via ICD-9-CM codes 401.xx--405.xx. ^b^CV events were defined as a primary or secondary diagnosis of MI, CHF, stroke, angina, CAD, CABG, percutaneous coronary intervention, angioplasty, CVD, PVD, ventricular arrhythmias, atrial fibrillation, supraventricular tachycardia or sinus tachycardia that occurred from 01/01/2007 to index date.*CABG* coronary artery bypass graft,*CAD* coronary artery disease,*CHF* congestive heart failure*, CV* cardiovascular,*CVD* cardiovascular disease,*ICD-9-CM* International Classification of Diseases, ninth revision, clinical modification,*MI* myocardial infarction,*PVD* peripheral vascular disease

Endpoints {#Sec5}
---------

The study endpoint was the risk of hospitalization due to a CV event during the follow-up period in patients with uncomplicated hypertension who newly initiated β-blocker monotherapy of nebivolol, atenolol, or metoprolol (determined via ICD-9-CM codes). Data were analyzed by hospitalizations due to individual CV events (MI, CHF, stroke, or angina pectoris) and due to a composite of CV events identified through inpatient claims with a principle diagnosis for any of the individual CV events. The ICD-9-CM codes used to identify MI were 410.xx and 412.xx; for CHF, the codes used were 428.xx, 402.01, 402.11, 402.91, 404.x1, and 404.x3; for stroke, 430.xx, 431.xx, 436.xx, 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, and 434.91; and for angina, 411.xx and 413.xx.

Statistical Analysis {#Sec6}
--------------------

The primary analysis consisted of propensity score-matching β-blocker cohorts using a pair-wise propensity score calculated via logistic regressions. Patients in the nebivolol cohort were 1:1 propensity matched two times: once to patients in the atenolol cohort and then again to those in the metoprolol cohort. Propensity matching was based on baseline demographics (age, sex, and geographical region; race was not included in the claims database), Charlson Comorbidity Index (CCI) score (a weighted index used to predict risk of death within 1 year of hospitalization in patients with certain comorbid diseases \[[@CR16], [@CR17]\]), diagnosis of comorbid chronic pulmonary disease, rheumatic disease, renal disease, and diabetes (per CCI), and use of other antihypertensive drugs during the baseline period. Additionally, the duration of the follow-up period was directly matched between cohorts. Balance between the cohorts was achieved via propensity score matching as determined by a standardized difference of \< 0.1 at *P *\> 0.05 for all variables included in the analysis. Time to first inpatient claim due to the composite CV event, as well as individual components of the composite, was assessed via multivariable Cox proportional hazards regression adjusting for the same covariates as those used in the propensity matching analysis. The hazard ratios (HR), 95% confidence interval (CIs), and statistical significance associated with the atenolol and metoprolol cohorts relative to nebivolol cohort were calculated.

The unadjusted incident rates of hospitalization due to the composite of CV event and its individual components were calculated as the number of patients with incident events divided by the total duration when the patients were at risk (per 1000 person-years). A 95% CI was calculated following Poisson distribution; the differences in incident rates were considered statistically significant if there was no overlap in 95% CIs. Analyses for this study were conducted using the Statistical Analysis System software (SAS; v 9.4) and Stata (v 12.0). All tests were two-tailed and conducted at a significance level of *α* \< 0.05.

Results {#Sec7}
=======

A total of 185,374 patients met inclusion criteria (*n* = 29,300 in nebivolol; *n* = 58,279 in atenolol; *n* = 97,795 in metoprolol). After propensity score matching, 81,402 were included (*n* = 27,134 in each of the nebivolol, atenolol, and metoprolol cohorts). Patients in the nebivolol, atenolol, and metoprolol groups were an average of 49.0 (standard deviation: 10.4), 48.9 (10.8), and 49.0 (10.8) years of age, respectively and 52% were female; the average duration of follow-up ranged from 260.7 to 265.1 days. During the 6-month pre-index baseline period, 34% of patients had used non-β-blocker antihypertensives. There were no statistical differences in the baseline demographics, comorbid conditions, use of any antihypertensive drugs during the pre-index period, or average duration of follow-up between the nebivolol cohort and either the atenolol or metoprolol cohorts (Table [1](#Tab1){ref-type="table"}).Table 1Baseline demographics and clinical characteristics of incident β-blocker monotherapy users (propensity score-matched cohorts)Nebivolol (*n* = 27,134)Atenolol (*n* = 27,134)Metoprolol (*n* = 27,134)Age, mean (SD), years49.0 (10.4)48.9 (10.8)49.0 (10.8)Males, %47.947.947.9Geographic region, % Northeast17.317.317.4 Midwest23.523.723.6 South52.552.452.4 West6.76.66.6CCI, mean (SD)1.4 (0.8)1.4 (0.8)1.4 (0.8)CCI categories, % 174.874.974.9 217.417.517.6 3+7.97.67.6CCI comorbidities (\> 1%), % Hypertension100100100 Depression7.97.97.9 Diabetes7.67.57.7 Chronic pulmonary disease5.95.85.8 Skin ulcer2.52.42.3 Malignancy2.42.32.3 Rheumatic disease1.00.80.9 Renal disease0.90.80.8Use of antihypertensives during baseline, % Any class33.933.833.7  β-blockers000  α-Blockers1.6**1.31.4**  Diuretics6.2**7.07.0**  Calcium channel blockers7.8**6.37.1**  ACE inhibitors10.4**12.713.1**  Angiotensin receptor blockers5.6**3.54.2**  Other antihypertensives12.1**11.39.9**Duration of follow-up, mean (SD), day264.8 (347.8)265.1 (348.6)260.7 (349.8)Incident β-blocker dose, mean (SD), mg/day\*7.4 (4.4)45.2 (26.9)57.1 (42.9)*Bold* indicates significance vs. nebivolol, *P *\< 0.05\*Statistical tests were not conducted for β-blocker daily dose during the follow-up*ACE* angiotensin-converting enzyme,*CCI* Charlson Comorbidity Index,*SD* standard deviation

After adjusting for baseline characteristics of the matched cohorts, the atenolol and metoprolol cohorts had a significantly greater risk of hospitalization due to a composite CV event (atenolol HR: 1.68 \[95% CI: 1.29--2.17\]; metoprolol: 2.05 \[1.59--2.63\]) vs. nebivolol (*P *\< 0.001, both; Fig. [2](#Fig2){ref-type="fig"}). Atenolol and metoprolol users also had significantly increased risks of MI (1.82 \[1.07--3.11\]; 1.78 \[1.04--3.06\]) and angina (1.77 \[1.19--2.64\]; 2.74 \[1.89--3.98\]) vs. nebivolol (*P *\< 0.05, all). CHF risk was significantly greater in the metoprolol cohort vs. nebivolol (2.26 \[1.17--4.36\]; *P *\< 0.05); for atenolol users, the hazard ratio was 1.58 (0.79--3.18) compared with nebivolol, but did not reach statistical significance. While the point estimates for stroke risk were greater for atenolol (1.54 \[0.90--2.64\]) and metoprolol (1.15 \[0.65--2.03\]) than nebivolol users, the differences were not statistically significant (see Table S1 in the electronic Supplementary Material for the full propensity-matched regression results).Fig. 2Adjusted hazard ratios (95% CI) of hospitalization due to CV events in propensity score-matched β-blocker users.*Red* or*bold* indicates significance vs. nebivolol, *P *\< 0.05. Hazard ratios were adjusted for demographics (age, sex, and geographical region), CCI score, diagnosis of chronic pulmonary disease, rheumatic disease, renal disease, or diabetes (per CCI), and use of other antihypertensive drugs during baseline.*CCI* Charlson Comorbidity Index,*CHF* congestive heart failure,*CI* confidence interval,*CV* cardiovascular,*MI* myocardial infarction

The unadjusted incidence rates \[95% CI\] of hospitalization due to a composite CV event (per 1000 person-years) in the matched cohorts were higher for the atenolol (7.80 \[6.61--9.13\]) and metoprolol cohorts (9.45 \[8.12--10.92\]) than for nebivolol (4.69 \[3.78--5.75\]; all *P *\< 0.05; Table [2](#Tab2){ref-type="table"}). For each individual component of the composite CV event, only the incidence rate for angina in the metoprolol cohort reached statistical significance (metoprolol 5.23 \[4.26--6.36\]; nebivolol: 1.93 \[1.37--2.65\]; *P *\< 0.05.Table 2Incidence rates (95% CI) of hospitalization due to CV events in propensity score-matched β-blocker users (per 1000 person-years)Nebivolol (*n* = 27,134)Atenolol (*n* = 27,134)Metoprolol (*n* = 27,134)Composite CV event4.69 (3.78, 5.75)**7.80 (6.61, 9.13)9.45 (8.12, 10.92)**MI1.07 (0.66, 1.63)1.93 (1.37, 2.65)1.86 (1.30, 2.58)CHF0.66 (0.35, 1.13)1.02 (0.62, 1.57)1.45 (0.96, 2.09)Stroke1.12 (0.70, 1.69)1.73 (1.20, 2.41)1.29 (0.84, 1.91)Angina1.93 (1.37, 2.65)3.41 (2.64, 4.33)**5.23 (4.26, 6.36)***Bold* indicates significance vs. nebivolol, *P *\< 0.05*CCI* Charlson Comorbidity Index,*CHF* congestive heart failure,*CI* confidence interval,*CV* cardiovascular,*MI* myocardial infarction

Discussion {#Sec8}
==========

In this large, retrospective, real-world cohort study of patients with uncomplicated hypertension, monotherapy with the β-blocker nebivolol was associated with a lower risk of hospitalization due to CV events than either atenolol or metoprolol monotherapy. In the US, β-blockers are no longer considered first-line treatments in uncomplicated hypertension \[[@CR8]\] as this drug class has been associated with increased CV risks compared with other antihypertensive classes \[[@CR3]--[@CR7]\]. Unfortunately, the majority of studies on which these conclusions were based used non-vasodilating β-blockers (mainly atenolol and metoprolol). While it is possible that the vasodilating blockers (carvedilol and nebivolol) may confer more consistent CV risk reductions due to their distinct hemodynamic mechanisms, further studies into possible differences of vasodilating versus non-vasodilating β-blockers on CV outcomes may better inform clinical decisions.

In studies comparing the effects of different β-blockers on measures of central blood pressure, an independent predictor of CV morbidity and mortality \[[@CR18]\], greater improvements occurred in hypertensive patients taking nebivolol than atenolol or metoprolol regardless of similar reductions in brachial blood pressure \[[@CR12], [@CR19]\]. Furthermore, nebivolol improves (i.e., reduces) the augmentation index independent of heart rate changes \[[@CR20]\], which could contribute to the reduced risk of MI and angina with nebivolol observed in our multivariable hazard regression analysis. Improvements in central blood pressure parameters with nebivolol may reflect its endothelium-dependent vasodilation via nitric oxide \[[@CR10]\].

Real-world data from the current study show that physicians prescribe β-blockers as monotherapy in treating hypertension and maintain patients at different doses than recommended in the prescribing inserts. For example, mean daily doses of atenolol (45.2 mg), and metoprolol tartrate (66.8 mg) were lower than recommended daily doses in the prescribing inserts (atenolol 50--100 mg \[25 mg for renally impaired patients\] \[[@CR21]\]); metoprolol tartrate 100--450 mg \[[@CR22]\]), while the daily nebivolol dose was at the low end of the recommended daily dose range (mean dose: 7.4 mg; recommended: 5--40 mg \[[@CR14]\]). It is possible that patients in the atenolol and metoprolol groups could have had greater reductions in CV event rates if they had been prescribed the recommended dosages; however, the data from large clinical trials in which atenolol was prescribed at the recommended dosages (50--100 mg/day) found that CV risks were higher with atenolol than with the comparator treatments \[[@CR6], [@CR7]\]. The real-world data from the present study indicate that atenolol and metoprolol are typically prescribed at lower than recommended monotherapy doses for hypertension, whereas nebivolol is prescribed within the recommended daily dose range. This apparent discrepancy in clinical use versus recommended use may be a reflection of physician experience. As such, it is important for the prescriber to not only consider data from prospectively designed clinical trials in which recommended doses were prescribed, but also those that are derived from real-world clinical experience wherein lower than recommended doses are often prescribed.

Many studies have shown that response to antihypertensive drugs can depend on individual patient characteristics, including age, race, ethnicity, sex, and genetic polymorphisms \[[@CR23]--[@CR25]\]. While nebivolol is effective and has a positive safety profile in many different hypertensive patient populations \[[@CR26]--[@CR29]\], the observed differences in CV event rates reported here may be due to dissimilarities in patient race or ethnicity across treatment cohorts. However, race and ethnicity were not captured in this dataset.

This study had several limitations due to the retrospective nature of the analyses. Despite the adjustments and matching for relevant baseline characteristics and demographics (except for race/ethnicity, which were not available in the database), unobserved differences due to treatment selection bias cannot be completely ruled out. Results may not be generalizable to uninsured populations, Medicaid recipients, or the US population as a whole. As medication use was assessed via pharmacy claims record, consumption of the medication cannot be confirmed. Prescribing bias due to physicians' prior experience with or knowledge of certain β-blockers cannot be ruled out. Patients with exclusionary medical conditions may have been included in this analysis as data coding may not have fully captured their medical histories. Blood pressure and heart rate information were only available for 10% of the study population in this claims database, and thus were not included in this analysis. Doses and dosages of other antihypertensive drugs used during baseline were not examined. As there was no wash-out period, we cannot account for any residual effects of baseline medications on the study outcomes. Finally, this study of β-blocker monotherapy may not be representative of real-world β-blocker use as 75% of hypertensive patients require combination antihypertensive treatment to control their BP \[[@CR30]\].

Conclusion {#Sec9}
==========

The results of this large retrospective, propensity-matched--cohort study of adult hypertensive patients are consistent with the notion that the large degree of heterogeneity among β-blockers may differentially impact CV outcomes. Long-term outcome studies are needed to fully examine how antihypertensive treatment with different β-blockers may affect CV event risk, especially when combined with other drug classes.
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